R

Rishab Ramapriyan

Brigham and Women's Hospital

ORCID: 0000-0002-2945-3236

Publishes on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Glioma Diagnosis and Treatment. 59 papers and 1.5k citations.

PubIndex Score39Top 61% · mid-careerHow it's scored

59Publications

1.5kTotal Citations

First publication: 2019First senior author: 2025

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Glioma Diagnosis and Treatment CAR-T cell therapy research Histone Deacetylase Inhibitors Research

Top publicationsby citations

Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023

Cited by 0

Data from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023

Cited by 0

Table S2 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023

Cited by 0

Table S3 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, David S. Hong, Vivek Verma et al.|Unknown|2023

Cited by 0

Supplementary Figure S1 from Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation–Related Abscopal Responses

James W. Welsh, David S. Hong, Chad Tang et al.|Unknown|2023

Cited by 0